share_log

Jefferies Initiates Coverage On ProKidney With Buy Rating, Announces Price Target of $15

Jefferies Initiates Coverage On ProKidney With Buy Rating, Announces Price Target of $15

富瑞集團以買入評級啟動對腎臟的覆蓋範圍,宣布目標價格為 15 美元
Benzinga Real-time News ·  2022/12/21 06:21

Jefferies analyst Kelly Shi initiates coverage on ProKidney (NASDAQ:PROK) with a Buy rating and announces Price Target of $15.

傑富瑞分析師Kelly Shih對ProKidney(納斯達克代碼:PROK)的報道給予買入評級,並宣佈目標價為15美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論